{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:38:08Z","timestamp":1792640288329,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016016","name":"Gilead UK and Ireland Corporate Contributions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Chest Medicine"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ccm.2021.11.009","type":"journal-article","created":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T06:05:04Z","timestamp":1645941904000},"page":"165-177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Antibiotic Management in Bronchiectasis"],"prefix":"10.1016","volume":"43","author":[{"given":"Charles S.","family":"Haworth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderigo Andres","family":"Floto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccm.2021.11.009_bib1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/thx.5.3.233","article-title":"Reduction in bronchial subdivision in bronchiectasis","volume":"5","author":"Reid","year":"1950","journal-title":"Thorax"},{"key":"10.1016\/j.ccm.2021.11.009_bib2","first-page":"6","article-title":"Inflammation: a two-edge sword \u2013 the model of bronchiectasis","volume":"69","author":"Cole","year":"1986","journal-title":"Eur J Respir Dis"},{"issue":"10150","key":"10.1016\/j.ccm.2021.11.009_bib3","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S0140-6736(18)31767-7","article-title":"Advances in bronchiectasis: endotyping, genetics, microbiome and disease heterogeneity","volume":"392","author":"Flume","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ccm.2021.11.009_bib4","doi-asserted-by":"crossref","first-page":"1700051","DOI":"10.1183\/13993003.00051-2017","article-title":"Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research","volume":"49","author":"Hill","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2021.11.009_bib5","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1136\/thx.41.7.559","article-title":"Short term response of patients with bronchiectasis to treatment with amoxicillin given in standard or high doses orally or by inhalation","volume":"41","author":"Hill","year":"1986","journal-title":"Thorax"},{"key":"10.1016\/j.ccm.2021.11.009_bib6","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/0954-6111(93)90072-8","article-title":"Effect of antibiotics on sputum inflammatory contents in acute exacerbations of bronchiectasis","volume":"87","author":"Ip","year":"1993","journal-title":"Respir Med"},{"key":"10.1016\/j.ccm.2021.11.009_bib7","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1183\/09031936.99.14512069","article-title":"A\u00a0comparative study on the efficacy of levofloxacin and ceftazidime in acute exacerbation of bronchiectasis","volume":"14","author":"Tsang","year":"1999","journal-title":"Eur Resp J"},{"key":"10.1016\/j.ccm.2021.11.009_bib8","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1378\/chest.130.5.1503","article-title":"Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis","volume":"130","author":"Bilton","year":"2006","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.ccm.2021.11.009_bib9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/1479972308091823","article-title":"Quality of life and inflammation in exacerbations of bronchiectasis","volume":"5","author":"Courtney","year":"2008","journal-title":"Chron Respir Dis"},{"key":"10.1016\/j.ccm.2021.11.009_bib10","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1183\/09031936.00122508","article-title":"Assessing response to treatment of exacerbations of bronchiectasis in adults","volume":"33","author":"Murray","year":"2009","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.ccm.2021.11.009_bib11","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201203-0487OC","article-title":"Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis","volume":"186","author":"Chalmers","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2021.11.009_bib12","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/thx.39.6.414","article-title":"Effect of antibiotic treatment on sputum elastase in bronchiectatic outpatients in a stable clinical state","volume":"39","author":"Stockley","year":"1984","journal-title":"Thorax"},{"key":"10.1016\/j.ccm.2021.11.009_bib13","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/thx.41.10.798","article-title":"Effect of short and long term antibiotic response on lung function in bronchiectasis","volume":"41","author":"Hill","year":"1986","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.ccm.2021.11.009_bib14","doi-asserted-by":"crossref","first-page":"1700629","DOI":"10.1183\/13993003.00629-2017","article-title":"European Respiratory Society guidelines for the management of adult bronchiectasis","volume":"50","author":"Polverino","year":"2017","journal-title":"Eur Respir J"},{"issue":"Suppl 1","key":"10.1016\/j.ccm.2021.11.009_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/thoraxjnl-2018-212463","article-title":"British Thoracic Society guideline for bronchiectasis in adults","volume":"74","author":"Hill","year":"2019","journal-title":"Thorax"},{"key":"10.1016\/j.ccm.2021.11.009_bib16","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0140-6736(96)05169-0","article-title":"Spread of a beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic","volume":"348","author":"Cheng","year":"1996","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ccm.2021.11.009_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002007.pub2","article-title":"Single versus combination intravenous antibiotic therapy for people with cystic fibrosis","volume":"18","author":"Elphick","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ccm.2021.11.009_bib18","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0022-3476(99)70197-6","article-title":"Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis","volume":"134","author":"Smith","year":"1999","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.ccm.2021.11.009_bib19","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/thx.2006.067595","article-title":"Survey of acute renal failure in patients with cystic fibrosis in the UK","volume":"62","author":"Bertenshaw","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.ccm.2021.11.009_bib20","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1136\/thx.2007.088757","article-title":"Case-control study of acute renal failure in patients with cystic fibrosis in the UK","volume":"63","author":"Smyth","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.ccm.2021.11.009_bib21","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(05)17906-9","article-title":"Once versus three-times daily regimen of tobramycin for pulmonary exacerbations of cystic fibrosis \u2013 the TOPIC study: a randomised controlled trial","volume":"365","author":"Smyth","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ccm.2021.11.009_bib22","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/jac\/dki146","article-title":"Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing","volume":"55","author":"Foweraker","year":"2005","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.ccm.2021.11.009_bib23","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/jac\/dkp007","article-title":"Variable antibiotic susceptibility in populations of Pseudomonas aeruginosa infecting patients with bronchiectasis","volume":"63","author":"Gillham","year":"2009","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.ccm.2021.11.009_bib24","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1378\/chest.123.5.1495","article-title":"Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration. Lack of association in cystic fibrosis","volume":"123","author":"Smith","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2021.11.009_bib25","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0140-6736(05)67060-2","article-title":"Combination antibiotic sensitivity testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial","volume":"366","author":"Aaron","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ccm.2021.11.009_bib26","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.rmed.2014.09.005","article-title":"Long-term macrolide maintenance therapy in non-CF bronchiectasis: evidence and questions","volume":"108","author":"Haworth","year":"2014","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.ccm.2021.11.009_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/qjmed\/hcs173","article-title":"Eight-weekly intravenous antibiotics is beneficial in severe bronchiectasis","volume":"106","author":"Mandal","year":"2013","journal-title":"QJM"},{"key":"10.1016\/j.ccm.2021.11.009_bib28","first-page":"255","article-title":"Prolonged antibiotic treatment of severe bronchiectasis; a report by a subcommittee of the antibiotics clinical trials (non-tuberculous) committee of the Medical Research Council","volume":"2","year":"1957","journal-title":"BMJ"},{"key":"10.1016\/j.ccm.2021.11.009_bib29","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1001\/archinte.1959.00270030001001","article-title":"Long-term treatment of bronchiectasis and chronic bronchitis. A.M.A","volume":"103","author":"Cherniack","year":"1959","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ccm.2021.11.009_bib30","first-page":"329","article-title":"Bacteriologic studies of the sputum in patients with chronic bronchitis and bronchiectasis. Results of continuous therapy with tetracycline, penicillin, or an oleandromycin-penicillin mixture","volume":"81","author":"Dowling","year":"1960","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.ccm.2021.11.009_bib31","first-page":"799","article-title":"Double-blind randomized study of prolonged higher-dose oral amoxicillin in purulent bronchiectasis","volume":"76","author":"Currie","year":"1990","journal-title":"Q\u00a0J Med"},{"key":"10.1016\/j.ccm.2021.11.009_bib32","first-page":"163","article-title":"The response of patients with purulent bronchiectasis to antibiotics for four months","volume":"250","author":"Hill","year":"1988","journal-title":"Q\u00a0J Med"},{"key":"10.1016\/j.ccm.2021.11.009_bib33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/jac\/34.1.149","article-title":"Efficacy and safety of long-term ciprofloxacin in the management of severe bronchiectasis","volume":"34","author":"Rayner","year":"1994","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.ccm.2021.11.009_bib34","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(12)60953-2","article-title":"Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial","volume":"380","author":"Wong","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ccm.2021.11.009_bib35","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial","volume":"309","author":"Altenburg","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ccm.2021.11.009_bib36","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.2013.2290","article-title":"Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non\u2013cystic fibrosis bronchiectasis","volume":"309","author":"Serisier","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ccm.2021.11.009_bib37","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-2600(19)30191-2","article-title":"Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis","volume":"7","author":"Chalmers","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"12","key":"10.1016\/j.ccm.2021.11.009_bib38","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S2213-2600(16)30320-4","article-title":"Comorbidities and the risk of mortality in patients with bronchiectasis: an international cohort study","volume":"4","author":"McDonnell","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ccm.2021.11.009_bib39","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S2213-2600(14)70165-1","article-title":"Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials","volume":"2","author":"Barker","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ccm.2021.11.009_bib40","doi-asserted-by":"crossref","first-page":"1702052","DOI":"10.1183\/13993003.02052-2017","article-title":"Respire 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"De Soyza","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2021.11.009_bib41","doi-asserted-by":"crossref","first-page":"1702053","DOI":"10.1183\/13993003.02053-2017","article-title":"Respire 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"Aksamit","year":"2018","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.ccm.2021.11.009_bib42","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-2600(18)30427-2","article-title":"Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials","volume":"7","author":"Haworth","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.ccm.2021.11.009_bib43","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S2213-2600(19)30185-7","article-title":"The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis","volume":"7","author":"Laska","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.ccm.2021.11.009_bib44","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1164\/rccm.201809-1651OC","article-title":"Airway bacterial load and inhaled antibiotic response in bronchiectasis","volume":"200","author":"Sibila","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2021.11.009_bib45","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1164\/rccm.201312-2208OC","article-title":"Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection","volume":"189","author":"Haworth","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.ccm.2021.11.009_bib46","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1164\/rccm.201005-0756OC","article-title":"A\u00a0randomised controlled trial of nebulised gentamicin in non-cystic fibrosis bronchiectasis","volume":"183","author":"Murray","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccm.2021.11.009_bib47","doi-asserted-by":"crossref","first-page":"2001451","DOI":"10.1183\/13993003.01451-2020","article-title":"Efficacy and safety of TOBI Podhaler in Pseudomonas aeruginosa-infected bronchiectasis patients: the iBEST study","volume":"57","author":"Loebinger","year":"2021","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.ccm.2021.11.009_bib48","doi-asserted-by":"crossref","first-page":"2000110","DOI":"10.1183\/13993003.00110-2020","article-title":"Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies","volume":"56","author":"Chalmers","year":"2020","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.ccm.2021.11.009_bib49","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1164\/rccm.201711-2202OC","article-title":"Characterization of the frequent exacerbator phenotype in bronchiectasis","volume":"197","author":"Chalmers","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.ccm.2021.11.009_bib50","first-page":"1602","article-title":"A\u00a0comprehensive analysis of Pseudomonas aeruginosa colonisation on prognosis in adult bronchiectasis","volume":"12","author":"Finch","year":"2015","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"10.1016\/j.ccm.2021.11.009_bib51","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1159\/000438490","article-title":"Eradication therapy against Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis","volume":"90","author":"Orriols","year":"2015","journal-title":"Respiration"}],"container-title":["Clinics in Chest Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523121012478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523121012478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:14:02Z","timestamp":1759454042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272523121012478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0272523121012478"],"URL":"https:\/\/doi.org\/10.1016\/j.ccm.2021.11.009","relation":{},"ISSN":["0272-5231"],"issn-type":[{"value":"0272-5231","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibiotic Management in Bronchiectasis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Chest Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccm.2021.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2021 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}